Markets
Sofi Surges on Student Loan limits in Senate Bill
(CSA Archives/Getty Images)

SoFi soars as GOP cuts to federal student loans move toward passage

Cuts to federal student loan programs would likely move more borrowers to private lenders.

Student loan lender SoFi Technologies hit its highest price since November 2021 on Monday as Senate Republicans moved forward on President Trump’s giant budget bill, which would cut federal student lending programs and likely push borrowers to private lenders like SoFi.

Trading in bullish call options surged on the day, helping to catalyze a run-up of more than 10% in early trading. The shares gave back some of those early gains, but remained up more than 6% in the last hour of trading.

As the Washington Post reported in May, the bill would radically change, and in some cases, complicate, the current student lending system in the US.

The bill includes changes like cutting the Pell grants used by students from poor and middle-class families, ending the federal PLUS loan programs for graduate students, and imposing new limits on the total amount that can be borrowed for advanced degrees, such as medicine and law, to $150,000 and $100,000 for master’s degrees. The Post reported:

“Republicans say imposing borrowing limits on graduate programs could force institutions to lower their costs. But the restrictions may simply drive more students to the private lending markets, where there are fewer consumer protections, said Jon Fansmith, senior vice president for government relations at the American Council on Education (ACE).”

That’s how SoFi CEO Anthony Noto seems to see the situation as well.

On the company’s post-earnings conference call in late April, he told analysts, “If the government backs away from providing in-school loans, Grad PLUS, et cetera, et cetera, we’ll absolutely capture that opportunity.”

More Markets

See all Markets
markets

Bullish options flows boost Rivian

EV maker Rivian is up nearly 5% on Monday afternoon as bullish options flows lift the stock ahead of its third-quarter earnings, set to drop next week.

According to Bloomberg, Rivian call options traded outnumber put options more than five to one, for a put/call ratio of less than 0.2 as of 2:38 p.m. ET. That’s significantly less than the 20-day put/call average of 0.4. More than 116,000 call options have changed hands, more than 60% above the full-day average over the past 20 days.

Rivian’s upcoming earnings will measure the automaker’s sales ahead of the expiration of the $7,500 EV tax credit. Since September, Rivian has performed two rounds of layoffs as it seeks to cut costs amid the end of regulatory credits and ahead of next year’s lower-cost SUV launch.

markets

Palantir inks defense deal with Poland, touches new intraday high

Palantir Technologies touched a new intraday high of $192.83 early Monday, as the company rode the China trade truce rally in AI tech stocks and retail favorites.

Palantir also signed a new deal to supply the government of Poland with data, AI, and cybersecurity software, according to Bloomberg.

Polish Minister of Defense Wladyslaw Kosiniak-Kamysz and Palantir CEO Alex Karp signed the letter of intent on the deal, about which few details were released. Polish officials did signal that they were interested in Palantir software systems for “battlefield management” and logistics. Up more than 150% this year, Palantir reports Q3 earnings on November 3.

Polish Minister of Defense Wladyslaw Kosiniak-Kamysz and Palantir CEO Alex Karp signed the letter of intent on the deal, about which few details were released. Polish officials did signal that they were interested in Palantir software systems for “battlefield management” and logistics. Up more than 150% this year, Palantir reports Q3 earnings on November 3.

markets

Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized

Intellia dropped sharply on Monday after it announced that it’s pausing two late-stage CRISPR gene-editing trials because one patient was hospitalized with liver damage.

Intellia had also disclosed in May that a patient had experienced elevated liver enzymes. The news is a major setback for the company, which currently has no products on the market and is working on a one-time treatment for heart and nerve conditions.

The news dragged down other companies working on CRISPR treatments, including Beam Therapeutics Inc, Crispr Therapeutics, Editas Medicine, and Prime Medicine.

markets

Gold craters as retail traders pull money from commodity ETFs

As its fierce rally begins to fade, it looks like retail traders are waving au revoir to gold.

JPMorgan strategist Arun Jain noted that retail traders have pulled about $120 million from commodity ETFs as of 11 a.m. ET on Monday, a level that stands in the 0.4th percentile relative to its one-year average. The SPDR Gold Shares ETF is down 2.8% as of 11:53 a.m. ET after suffering its worst loss since April 2013 last Tuesday. That day, retail had pulled just $50 million from commodity ETFs by 11 a.m.

The five-session average daily flows into the product hit an all-time high of nearly $1.1 billion last Monday as gold and silver had effectively become the new meme stocks, displaying strong momentum and heavy options activity.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.